-
Under the agreement, McKinsey must establish a fund to reimburse insurers, private benefit plans and others for some or all of their prescription opioid costs.
-
Hospitals rely on scores of generic drugs given by injection. But these workhorses are often in short supply. Cheap prices have led to factory closures that leave the supply chain vulnerable.
-
AHCA Secretary Jason Weida told a state House panel he is “cautiously optimistic” the FDA will approve the plan, which the state has been pursuing since 2019.
-
The White House unveiled a list of 48 drugs whose prices increased faster than the rate of inflation this year. Under a new law, drugmakers must pay rebates to the government because of it.
-
Colorado officials say they haven’t been able to stand up a program to import drugs from Canada because of drugmaker opposition — and the Biden administration’s inaction.
-
States and counties look to expand programs that accept donations of unused surplus drugs from places like nursing homes and hospitals and redistribute them to low-income and uninsured residents.
-
One common decongestant, phenylephrine, was found ineffective this fall. Doctors are skeptical about the rest of the over-the-counter cold cures lineup.
-
The governors square off in a first-of-its-kind debate Thursday. Let's compare the political rivals’ health care positions, showing how their policies helped — or hinder— the health of their states’ residents.
-
The prevalence of synthetic drugs is undercutting a previously effective and widely embraced treatment tactic. Now, the model pioneered in Vermont a decade ago and adopted nationwide is being forced to evolve.
-
A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, but some pharmacists say it’s enabling these price brokers to simply do new things unfairly.